News
Diabetics given the pill called orforglipron lost 16 pounds, or 7.9% of their body weight, over a 40-week period.
Novo Nordisk, the maker of Ozempic and Wegovy, has also jumped into the legal fight —this time by intervening in the OFA’s lawsuit against the FDA. The company supports the agency’s move to restrict ...
“Our CB-SCs can target different compartments of the immune system, educating and correcting their dysfunctions at a fundamental level,” says Dr. Zhao. “This therapy has the potential to revolutionize ...
Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...
Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of ...
The drugmaker Lilly announced topline results of a clinical trial of a new pill in the same drug class as injectables like ...
Appetite-suppressing medications that an estimated 10% of American adults use are disrupting grocery shopping.
Eli Lilly’s latest innovation, orforglipron, has emerged as a formidable contender in the weight-loss medication arena. The pill has demonstrated comparable results to Ozempic, a leading injectable ...
The Gila monster is a large, magnificent, and venomous desert-dwelling reptile found throughout the southwestern US and Mexico. A toxic bite from the Gila can cause searing pain, loss of consciousness ...
Wellness startups are launching products that target the natural growth of GLP-1, the hormone that medicines like Ozempic and ...
Recent consumer research by product development group AMC Global and OpinionRoute, LLC reveals the evolving preferences of ...
Eli Lilly has met its goal of achieving semaglutide-like efficacy with an oral GLP-1 drug. | Eli Lilly has met its goal of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results